HK1191643A1 - -芳基不飽和稠環叔胺類化合物及其製備方法和抗腫瘤應用 - Google Patents

-芳基不飽和稠環叔胺類化合物及其製備方法和抗腫瘤應用

Info

Publication number
HK1191643A1
HK1191643A1 HK14104728.5A HK14104728A HK1191643A1 HK 1191643 A1 HK1191643 A1 HK 1191643A1 HK 14104728 A HK14104728 A HK 14104728A HK 1191643 A1 HK1191643 A1 HK 1191643A1
Authority
HK
Hong Kong
Prior art keywords
preparation
tertiary amine
amine compound
fused ring
unsaturated fused
Prior art date
Application number
HK14104728.5A
Other languages
English (en)
Inventor
謝藍
王曉鋒
李國雄
Original Assignee
中國人民解放軍軍事醫學科學院毒物藥物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中國人民解放軍軍事醫學科學院毒物藥物研究所 filed Critical 中國人民解放軍軍事醫學科學院毒物藥物研究所
Publication of HK1191643A1 publication Critical patent/HK1191643A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK14104728.5A 2012-05-31 2014-05-20 -芳基不飽和稠環叔胺類化合物及其製備方法和抗腫瘤應用 HK1191643A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012101764545A CN102786512A (zh) 2012-05-31 2012-05-31 N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用
PCT/CN2013/076457 WO2013178075A1 (zh) 2012-05-31 2013-05-30 N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用

Publications (1)

Publication Number Publication Date
HK1191643A1 true HK1191643A1 (zh) 2014-08-01

Family

ID=47152117

Family Applications (2)

Application Number Title Priority Date Filing Date
HK14104728.5A HK1191643A1 (zh) 2012-05-31 2014-05-20 -芳基不飽和稠環叔胺類化合物及其製備方法和抗腫瘤應用
HK15104889.9A HK1206007A1 (zh) 2012-05-31 2015-05-22 -芳基不飽和稠環叔胺類化合物及其製備方法和抗腫瘤應用

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15104889.9A HK1206007A1 (zh) 2012-05-31 2015-05-22 -芳基不飽和稠環叔胺類化合物及其製備方法和抗腫瘤應用

Country Status (6)

Country Link
US (1) US9751884B2 (zh)
EP (1) EP2857393B1 (zh)
JP (1) JP6096891B2 (zh)
CN (2) CN102786512A (zh)
HK (2) HK1191643A1 (zh)
WO (1) WO2013178075A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102786512A (zh) 2012-05-31 2012-11-21 中国人民解放军军事医学科学院毒物药物研究所 N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用
PL3177612T3 (pl) 2014-08-04 2022-08-08 Nuevolution A/S Opcjonalnie skondensowane pochodne pirymidyny podstawione heterocyklilem, użyteczne w leczeniu chorób zapalnych, metabolicznych, onkologicznych i autoimmunologicznych
CN105153046A (zh) * 2015-08-25 2015-12-16 佛山市赛维斯医药科技有限公司 双卤素取代的乙氧基苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN105153047A (zh) * 2015-08-25 2015-12-16 佛山市赛维斯医药科技有限公司 含新型苯并喹唑啉和邻位氟结构的酪氨酸激酶抑制剂及用途
AU2018352695A1 (en) 2017-10-19 2020-05-28 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
KR20220155593A (ko) 2020-03-19 2022-11-23 아르커스 바이오사이언시즈 인코포레이티드 Hif-2알파의 억제제로서의 테트랄린 및 테트라히드로퀴놀린 화합물
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
IL307700A (en) * 2021-04-20 2023-12-01 Univ Tennessee Res Found Metabolically stable pyrimidinyl dihydroquinoxalinones as tubulin polymerization inhibitors
CN114436975B (zh) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基喹唑啉类化合物及其应用
CN116354953B (zh) * 2022-12-31 2024-07-16 西北农林科技大学 含苯并噻唑类化合物的除草组合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL292083A (zh) 1962-09-18
DE2165310A1 (de) 1971-12-29 1973-07-12 Boehringer Sohn Ingelheim Neue 1-aryl-3,4-dihydro-(2h,5h)-1,4benzodiazepin-5-one und verfahren zu ihrer herstellung
US4532333A (en) 1982-04-12 1985-07-30 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines
JPS60224673A (ja) 1984-04-24 1985-11-09 ヘキスト−ルセル・フア−マシユウテイカルズ・インコ−ポレイテツド １−（アミノアルキルフエニルおよびアミノアルキルベンジル）インド−ルおよびインドリン
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9306587D0 (en) 1993-03-30 1993-05-26 Pilkington Plc Photochromic compounds
JP2890267B2 (ja) * 1994-02-23 1999-05-10 ファイザー インク． ４−ヘテロサイクリル−置換キナゾリン誘導体、その調製法および抗癌剤としてのその使用法
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
RU2003135424A (ru) 2001-05-14 2005-05-20 Бристол-Маерс Сквибб Фарма Компани (Us) Замещенные пиразиноны, пиридины и пиримидины в качестве лигандов кортикотропин высвобождающего фактора
JP2003321451A (ja) 2002-05-07 2003-11-11 Fuji Photo Film Co Ltd ジアゾニウム塩およびそれを用いた感熱記録材料
AU2003247141A1 (en) 2002-08-01 2004-02-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
PE20060572A1 (es) 2004-07-27 2006-06-27 Novartis Ag Compuestos de benzoimidazolona como inhibidores de hsp90
US20090069360A1 (en) * 2006-03-16 2009-03-12 David Bryant Batt Organic Compounds
JP2011116663A (ja) 2008-05-30 2011-06-16 Otsuka Pharmaceut Co Ltd ベンゾジアゼピン化合物
CA2765819A1 (en) * 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses as inhibitors of pi3 k activity
JP2013544826A (ja) * 2010-11-24 2013-12-19 エクセリクシス， インク． ＰＩ３Ｋ／ｍＴＯＲの阻害剤としてのベンゾオキサゼピン類ならびにそれらの使用法および製造法
CA2826295C (en) 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
US9616064B2 (en) * 2011-03-30 2017-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rho kinase inhibitors and methods of use
AR086798A1 (es) 2011-06-29 2014-01-22 Otsuka Pharma Co Ltd Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen
CN102786512A (zh) * 2012-05-31 2012-11-21 中国人民解放军军事医学科学院毒物药物研究所 N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用

Also Published As

Publication number Publication date
EP2857393A1 (en) 2015-04-08
JP2015518864A (ja) 2015-07-06
US20150141407A1 (en) 2015-05-21
EP2857393B1 (en) 2018-09-12
CN103608341A (zh) 2014-02-26
JP6096891B2 (ja) 2017-03-15
US9751884B2 (en) 2017-09-05
CN102786512A (zh) 2012-11-21
CN103608341B (zh) 2015-11-25
EP2857393A4 (en) 2015-12-23
HK1206007A1 (zh) 2015-12-31
WO2013178075A1 (zh) 2013-12-05

Similar Documents

Publication Publication Date Title
HK1206007A1 (zh) -芳基不飽和稠環叔胺類化合物及其製備方法和抗腫瘤應用
HK1216538A1 (zh) 人類微管相關蛋白抗體
EP2832526A4 (en) METHOD FOR MANUFACTURING JOINT ELEMENT AND JOINT ELEMENT
GB201520943D0 (en) Novel linker and preparation method thereof
EP2842935A4 (en) MANNICH-BASE, MANUFACTURING METHOD AND APPLICATION THEREOF
HK1201727A1 (zh) 抗癌融合蛋白
EP2837491A4 (en) PROCESS FOR PRODUCING ASSEMBLED ELEMENT AND ASSEMBLED ELEMENT
EP2805955A4 (en) 1-OXO / ACYLATION-14-ACYLATED ORIDONE DERIVATIVE, METHOD OF MANUFACTURING THEREOF AND USE THEREOF
EP2881640A4 (en) FITTING, AND RING, AND METHOD OF MANUFACTURING THE SAME
HK1201848A1 (zh) 抗癌融合蛋白
IL226205A0 (en) anticancer fusion protein
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
ZA201308597B (en) Anticancer fusion protein
PT2918593T (pt) Polimorfos de benfotiamina, seu método de preparação e utilização
EP2805954A4 (en) 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE AND MANUFACTURING METHOD AND USE THEREOF
EP2805946A4 (en) AMINO-ETHEROARYL COMPOUND, METHOD OF MANUFACTURING THEREOF AND USE THEREOF
GB2503388B (en) Sealing ring and preparation method thereof
EP2821389A4 (en) PROCESS FOR PRODUCING COMPOUND COMPRISING AN AMINO GROUP AND / OR A HYDROXYL GROUP
EP2941447A4 (en) NOVEL POLYAMIDE, PROCESS FOR PREPARING THE SAME AND USES THEREOF
EP2913399A4 (en) METHOD OF PREPARING RNA
EP3067344A4 (en) Method for preparing lacosamide
EP2660237A4 (en) METHOD OF PREPARING TERTIARY AMINE
PL398496A1 (pl) Iminowa pochodna (-)-fenchonu i sposób jej wytwarzania

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210528